Avelumab and Merkel Cell Carcinoma: How Immune Checkpoint Inhibition Affects Pathophysiology

From General Immunology to Occupational Health

The legacy of general health and science information has long provided a foundation for understanding how biological systems respond to external agents. Within this broad context, the immune system’s role in surveillance and regulation has been a central theme, particularly in relation to environmental exposures. The transition from this heritage to a more focused occupational concern begins with recognizing that certain therapeutic interventions, such as immune checkpoint inhibitors, represent a deliberate manipulation of immune pathways. Avelumab, a monoclonal antibody targeting PD-L1, exemplifies this class of agents used in oncology. Its administration introduces a controlled perturbation of immune homeostasis, which, in the context of mass production environments, raises questions about unintended consequences. The occupational exposure concern emerges when considering that workers involved in the manufacturing or handling of such biologics may encounter the compound through inhalation or dermal contact. This shifts the perspective from a clinical therapeutic setting to a workplace safety paradigm. The bridge concept thus pivots from general immunology education to a specific risk assessment: how exposure to Avelumab in production settings could influence the pathophysiology of Merkel cell carcinoma. This transition maintains a neutral academic tone, avoiding mechanistic claims while framing the occupational dimension as a logical extension of legacy health science principles.

Avelumab: Mechanism of Action and Clinical Use in Merkel Cell Carcinoma

Avelumab is a fully human IgG1 monoclonal antibody that functions as an immune checkpoint inhibitor by targeting programmed cell death ligand 1 (PD-L1) (https://pubmed.ncbi.nlm.nih.gov/29799096). It was approved in the USA, the EU, and Japan for the treatment of metastatic Merkel cell carcinoma (MCC), making it the first therapeutic agent specifically approved for this indication (https://pubmed.ncbi.nlm.nih.gov/29799096). Approval was based on the two-part, single-arm, phase II trial JAVELIN Merkel 200, in which confirmed objective responses were observed in approximately one-third of patients with chemotherapy-refractory metastatic MCC treated with avelumab (https://pubmed.ncbi.nlm.nih.gov/29799096). Merkel cell carcinoma is a rare and aggressive neuroendocrine cutaneous malignancy with poor prognosis (https://pubmed.ncbi.nlm.nih.gov/33439294). Approximately 80% of cases are caused by the human Merkel cell polyomavirus, while the remaining 20% are induced by UV light leading to mutations (https://pubmed.ncbi.nlm.nih.gov/34445385). The standard treatment for metastatic MCC is the use of anti-PD-1/PD-L1 immune checkpoint inhibitors such as avelumab, which in comparison with conventional chemotherapy show better overall response rates and longer duration of responses (https://pubmed.ncbi.nlm.nih.gov/34445385).

Pathophysiological Effects and Immune-Related Adverse Events

The mechanistic pathway linking avelumab to MCC pathophysiology is primarily through its role as an immune checkpoint inhibitor. Avelumab blocks PD-L1, thereby preventing the suppression of T-cell activity against tumor cells. In MCC, this can lead to overactivation of the immune system, causing immune-related adverse events (irAEs) (https://pubmed.ncbi.nlm.nih.gov/31543781). One reported case describes hypercalcemia secondary to reactivation of sarcoidosis in a patient with metastatic MCC on avelumab, which was managed with corticosteroids to full resolution, and avelumab therapy was safely continued (https://pubmed.ncbi.nlm.nih.gov/31543781). For avelumab-refractory patients, efficient and safe treatment options are lacking, though combined ipilimumab and nivolumab has shown activity in some cases (https://pubmed.ncbi.nlm.nih.gov/33439294). In a multicenter study, three out of five patients with avelumab-refractory MCC responded to combined ipilimumab and nivolumab according to RECIST 1.1 (https://pubmed.ncbi.nlm.nih.gov/33439294). Immune checkpoint inhibition has significantly improved treatment outcomes in metastatic disease, with response rates to PD-1/PD-L1 inhibition of up to 62% (https://pubmed.ncbi.nlm.nih.gov/36450381).

Causation and Risk Considerations for Occupational Exposure

Regarding causation-related considerations for affected patients, the timeline between avelumab exposure and documented harm is variable. In the JAVELIN Merkel 200 trial, responses were observed in approximately one-third of patients, but irAEs can occur at any time during treatment. The case of hypercalcemia due to sarcoidosis reactivation occurred during avelumab treatment for metastatic MCC (https://pubmed.ncbi.nlm.nih.gov/31543781). For patients who become refractory to avelumab, subsequent treatment with combined ipilimumab and nivolumab may be considered, though data are limited to small retrospective studies (https://pubmed.ncbi.nlm.nih.gov/33439294, https://pubmed.ncbi.nlm.nih.gov/36450381). The adequacy of warnings regarding avelumab and MCC is supported by the drug's approval specifically for this indication, which implies that healthcare providers are informed of its use and potential adverse effects. However, the risk of irAEs, including rare events like sarcoidosis reactivation, should be clearly communicated to patients. The evidence indicates that avelumab is a first-line therapy for metastatic MCC, but its use requires monitoring for immune-related toxicities. For affected patients, the causation between avelumab and MCC pathophysiology is indirect: avelumab does not cause MCC but rather treats it by modulating the immune response. The harm associated with avelumab is primarily through irAEs, which are a known risk of immune checkpoint inhibitors. In summary, avelumab is an effective treatment for metastatic MCC, with a mechanism of action that involves blocking PD-L1 to enhance T-cell activity against tumors. While it improves outcomes for many patients, it carries a risk of irAEs that require careful management. The timeline between exposure and harm varies, and for patients who do not respond or become refractory, alternative therapies such as combined ipilimumab and nivolumab may be considered.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is avelumab and how does it work in Merkel cell carcinoma?

Avelumab is a fully human IgG1 monoclonal antibody that functions as an immune checkpoint inhibitor by targeting programmed cell death ligand 1 (PD-L1) (https://pubmed.ncbi.nlm.nih.gov/29799096). It blocks PD-L1, thereby preventing the suppression of T-cell activity against tumor cells, which enhances the immune response against Merkel cell carcinoma.

What are the risks of immune-related adverse events with avelumab?

Avelumab can cause immune-related adverse events (irAEs) due to overactivation of the immune system. One reported case describes hypercalcemia secondary to reactivation of sarcoidosis in a patient with metastatic MCC on avelumab (https://pubmed.ncbi.nlm.nih.gov/31543781). Other irAEs may occur and require careful management.

Is there a link between occupational exposure to avelumab and Merkel cell carcinoma?

Occupational exposure to avelumab in manufacturing or handling settings is a theoretical concern, but current evidence does not establish a direct causal link between avelumab exposure and the development of Merkel cell carcinoma. Avelumab is used to treat MCC, not cause it. However, workers may be at risk for immune-related effects if exposed.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Avelumab exposure and a confirmed Merkel Cell Carcinoma diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.